Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

David Darst, M.B.A.

Chief Operating Officer

David co-leads Inspirna’s financing, business and corporate development, and drug development efforts. As COO, he is responsible for implementing the company’s strategic and operational objectives through its intellectual property generation and prosecution, licensing activities, budgeting, and cross-functional CMC, nonclinical, and clinical efforts. Prior to joining Inspirna, he was a venture capitalist at OrbiMed Advisors, the world’s largest private healthcare dedicated investment firm. There, he invested in leading private and public companies developing therapeutics for life-threatening and debilitating disorders. 

David was a co-founder and Director of Potentia Pharmaceuticals, which sold its assets to its spin-out company Apellis Pharmaceuticals (NASDAQ: APLS). Apellis’ complement inhibitor, Pegcetacoplan (EMPAVELI), is FDA and European Commission approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and is in late-stage clinical trials for geographic atrophy / age-related macular degeneration and other autoimmune disorders. David has an M.B.A. from Harvard Business School and a B.A., cum laude, from Harvard College. He is a Director of the Alliance for Cancer Gene Therapy (ACGT) and sits on the Rockefeller University Advisory Council.